Recent Developments in the Pharma Sector: Complementary Research on AVEO Oncology, Capnia, 22nd Century Group, Biodel, and Discovery Laboratories

NEW YORK, April 24, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including AVEO Oncology (NASDAQ: AVEO), Capnia, Inc. (NASDAQ: CAPN), 22nd Century Group, Inc. (NYSEMKT: XXII), Biodel Inc. (NASDAQ: BIOD), and Discovery Laboratories, Inc. (NASDAQ: DSCO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

AVEO Research Report: ( http://get.analystsreview.com/pdf/?c=AVEO%20Oncology&d=24-Apr-2015&s=AVEO ),

CAPN Research Report: ( http://get.analystsreview.com/pdf/?c=Capnia&d=24-Apr-2015&s=CAPN ),

XXII Research Report: ( http://get.analystsreview.com/pdf/?c=22nd%20Century%20Group&d=24-Apr-2015&s=XXII ),

BIOD Research Report: ( http://get.analystsreview.com/pdf/?c=Biodel&d=24-Apr-2015&s=BIOD ),

DSCO Research Report: ( http://get.analystsreview.com/pdf/?c=Discovery%20Laboratories&d=24-Apr-2015&s=DSCO ).

============

--

Analyst Update: Financial Results, Appointments, Events, Positive Results from Studies, and Enrollment in Trials

Reviewed by: Rohit Tuli, CFA®  

U.S. stocks continued to surge to record highs on Thursday as the Nasdaq Composite closed at its highest level ever, supported by better than expected corporate earnings. The Nasdaq Composite gained 0.41%, or 20.89 points to close at an all-time record high of 5056.06. The S&P 500 advanced 0.24%, or 4.97 points to 2112.93, and the Dow Jones Industrial Average closed the session at 18,058.69, up 0.11% or 20.42 points. European stocks mostly closed lower on Thursday as investors remained vigil on Greece's debt turmoil and cash crunch situation. Germany's DAX 30 and France's CAC 40 dropped 1.21% and 0.62%, respectively, while London's FTSE 100 gained modestly by 0.3% on Thursday. Meanwhile, Asian stock markets mostly advanced on Thursday as the Shanghai Composite and Japan's Nikkei both closed higher.

AVEO Oncology announced its 2014 financial results with total collaboration revenue of $18.1 million compared with $1.3 million in 2013. Net loss for 2014 stood at $52.7 million, or $1.01 per diluted share compared with net loss of $107.0 million or $2.10 per diluted share for 2013.

Capnia, Inc. (Capnia) has appointed Edward Ebbers as its Chief Commercial Officer with responsibilities for leading Capnia's commercial organization, including managing the ongoing commercial rollout of the Company's lead product, CoSense®.

On March 25, 2015, 22nd Century Group, Inc. (22nd Century Group) announced that David Sweanor, Adjunct Professor of Law, University of Ottawa, will present the keynote address at 22nd Century Group's annual shareholder meeting scheduled on Saturday, April 25, 2015.

Biodel Inc. (Biodel) has announced results from a formative human factors study of its Glucagon Emergency Management (GEM) device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon.

On April 16, 2015, Discovery Laboratories, Inc. (Discovery Laboratories) announced the completion of enrollment in its AEROSURF® phase 2a clinical trial. The Company is also implementing a restructuring plan to voluntarily cease the commercialization of SURFAXIN® (lucinactant) Intratracheal Suspension and focus its resources on the development of its aerosolized KL4 surfactant for respiratory diseases, beginning with AEROSURF.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review